1. Home
  2. UTHR vs BLDR Comparison

UTHR vs BLDR Comparison

Compare UTHR & BLDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • BLDR
  • Stock Information
  • Founded
  • UTHR 1996
  • BLDR 1998
  • Country
  • UTHR United States
  • BLDR United States
  • Employees
  • UTHR N/A
  • BLDR N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • BLDR RETAIL: Building Materials
  • Sector
  • UTHR Health Care
  • BLDR Consumer Discretionary
  • Exchange
  • UTHR Nasdaq
  • BLDR Nasdaq
  • Market Cap
  • UTHR 13.8B
  • BLDR 12.4B
  • IPO Year
  • UTHR 1999
  • BLDR 2005
  • Fundamental
  • Price
  • UTHR $303.96
  • BLDR $138.25
  • Analyst Decision
  • UTHR Buy
  • BLDR Buy
  • Analyst Count
  • UTHR 13
  • BLDR 17
  • Target Price
  • UTHR $382.00
  • BLDR $151.41
  • AVG Volume (30 Days)
  • UTHR 694.7K
  • BLDR 2.1M
  • Earning Date
  • UTHR 10-29-2025
  • BLDR 07-31-2025
  • Dividend Yield
  • UTHR N/A
  • BLDR N/A
  • EPS Growth
  • UTHR 17.94
  • BLDR N/A
  • EPS
  • UTHR 25.63
  • BLDR 6.61
  • Revenue
  • UTHR $3,077,800,000.00
  • BLDR $15,944,360,000.00
  • Revenue This Year
  • UTHR $13.89
  • BLDR N/A
  • Revenue Next Year
  • UTHR $5.68
  • BLDR $1.59
  • P/E Ratio
  • UTHR $11.89
  • BLDR $20.97
  • Revenue Growth
  • UTHR 17.62
  • BLDR N/A
  • 52 Week Low
  • UTHR $266.98
  • BLDR $102.60
  • 52 Week High
  • UTHR $417.82
  • BLDR $203.14
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 52.97
  • BLDR 55.68
  • Support Level
  • UTHR $302.19
  • BLDR $138.89
  • Resistance Level
  • UTHR $312.44
  • BLDR $144.00
  • Average True Range (ATR)
  • UTHR 6.59
  • BLDR 4.97
  • MACD
  • UTHR -0.48
  • BLDR 0.02
  • Stochastic Oscillator
  • UTHR 60.65
  • BLDR 67.66

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About BLDR Builders FirstSource Inc.

Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.

Share on Social Networks: